Our Science
Novel Cargo Combined with Programmable Delivery.
nChroma Bio is optimizing the selection of innovative cargos with in vivo delivery technologies to develop targeted therapies across a broad array of diseases and tissue types.
Overview
One of the greatest challenges in genetic medicine today is achieving safe, efficient, and effective tissue-specific delivery of therapeutic molecules in vivo—particularly outside of the liver.
nChroma Bio is working to address this challenge by combining disease-specific genetic cargos with delivery systems tailored to their biological context.
Leveraging a modular technology suite that enables precise, tissue-specific delivery of complex genetic payloads, nChroma utilizes lipid nanoparticles (LNPs) for liver-specific applications, and engineered virus-like particles (eVLPs) for extrahepatic delivery. This modularity enables the precise and efficient in vivo delivery of a wide range of therapeutic agents, expanding the potential impact of epigenetic and gene editing across both hepatic and extrahepatic indications.
Epigenetic Therapeutics
What is Epigenetics?
Epigenetics is the body’s natural system for regulating gene expression, dictating how, when, and where genes are activated or silenced without altering the underlying DNA sequence.
Although all cells share the same genome, epigenetics enables them to adopt distinct identities and functions by establishing stable, cell-specific patterns of gene activity. This system works by adding chemical tags, such as methyl groups, to DNA or associated proteins, which determine the accessibility of genes to the cellular machinery responsible for transcription. These epigenetic marks play a key role in maintaining each cell’s unique identity over time and are crucial in both normal development and disease processes.
Extrahepatic Delivery
What are DLVR Particles?
Extrahepatic means outside of the liver. nChroma Bio is developing novel particles for optimized extrahepatic delivery of gene editing agents.
By enabling in vivo, tissue-specific delivery, nChroma’s DLVR particles offer the potential for:
- Targeted delivery of active pharmaceutical ingredient (API)
- Programmable specificity
- Large & diverse cargo capabilities
- Scalable manufacturing
DLVR uses engineered virus-like particles (eVLPs) to deliver ribonucleoprotein (RNP) forms of gene editors—such as base editors, prime editors, and CRISPR/Cas—into extrahepatic tissues enabling a precise and targeted means of gene modification for non-liver-specific indications.
Partnerships
Collaboration Fuels Discovery and Expands Possibility
Our modular delivery solutions and diverse therapeutic cargos are built to support strategic partnerships—advancing science and accelerating the development of new medicines for patients.
